Compelling Growth Metrics
Strong fundamentals and market leadership position us for continued exponential growth
Market Size
Global genomics market projected by 2028The precision medicine market is experiencing unprecedented growth, driven by advances in AI and declining sequencing costs.
Revenue Growth
Year-over-year revenue increaseConsistent triple-digit growth driven by expanding test portfolio and global market penetration.
Customer Retention
Healthcare provider retention rateIndustry-leading retention demonstrates the value and reliability of our genetic testing platform.
Partner Network
Healthcare facilities worldwideStrategic partnerships with hospitals, clinics, and research institutions across 45+ countries.
Massive Addressable Market
[ Market Opportunity ]The global precision medicine market is projected to reach $217.8 billion by 2028, with genomics testing representing $66.5B+ growing at 19.4% CAGR
Pharmacogenomics
$15.8B+13.2% CAGRPersonalized medication optimization based on genetic profiles
Oncology Testing
$28.4B+15.7% CAGRHereditary cancer risk assessment and early detection
Nutrigenomics
$12.6B+17.8% CAGRDiet and nutrition optimization through genetic insights
Carrier Screening
$9.7B+12.9% CAGRReproductive health and family planning genetics
Growth Timeline
[ Our Journey ]From a bold idea in 2017 to a global genomics leader
Company Founded
Gene Matrix AI launched with a vision to democratize genetic testing through AI-powered analysis and precision medicine.
Day One VisionCLIA & CE-IVD Certification
Achieved CLIA certification and CE-IVD Certified status, establishing our laboratory as a gold standard in clinical genetic testing.
Dual AccreditationFirst Product Launch
Released GeneCore comprehensive health panel, achieving a landmark 100,000 tests processed within the first year.
100K Tests ProcessedProvider Network Expansion
Onboarded 500+ healthcare providers and clinic partners across North America, building a robust clinical distribution network.
500+ Provider PartnersGlobal Expansion
Expanded operations into Europe and the Middle East, partnering with 300+ healthcare facilities across 12 countries including the UK, Germany, UAE, and Canada.
12 CountriesAI Platform Launch
Launched our proprietary AI genomics engine delivering 99.9% accuracy, real-time variant interpretation, and personalized health insights at scale.
99.9% AI AccuracyMarket Leadership
Reached 1M+ tests processed, recognized as a top-tier genomics platform with 850+ partner facilities across 12 countries.
1M+ Tests ProcessedSeries A Funding — Coming Soon
Preparing to launch our Series A funding round to accelerate global expansion, deepen AI capabilities, and scale our provider network worldwide.
Target: $75MWorld-Class Team
[ Leadership ]Industry veterans with proven track records in genomics, AI, and scaling healthcare companies
Tarek Younis
Chief Executive OfficerTarek Younis is the visionary founder and CEO of Gene Matrix AI, leading the company's mission to revolutionize healthcare through AI-powered genetic diagnostics. With over 15 years of experience in healthcare technology and biotechnology.
Dr. James Chen
Chief Scientific OfficerLammy Shaheen
Executive Director of Business & OperationsSaso Poposki
President of European OperationsDr. Michael Okonkwo
Chief Medical OfficerDr. Amara Nkosi
Director of African MarketsDr. Eric Lander
Former Science Advisor to President — Broad InstituteMary Meeker
General Partner — Bond CapitalDr. Francis Collins
Former NIH Director — NIHJohn Doerr
Chairman — Kleiner PerkinsPartner With Innovation
[ Get In Touch ]Submit your inquiry to join our investment community and be part of the genomics revolution
investors@genematrix.io
(847) 302-9668
Book a Call
Schedule a meeting with our investor relations team.
Invest in the Future of Genomics
Join us in revolutionizing personalized medicine through AI-powered genetic analysis. A $217B+ market opportunity with exponential growth potential.